Correction in CRPC CUA guideline.
In the recent CUA Guideline on the management of CRPC, (1) there was a missing word in the caption for Figure 1.
Published online December 14, 2015.
(1.) Saad F, Chi KN, Finelli A, et al. The 2015 CUA-CUOG Guideline for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2015;9:90-6. http://dx.doi.org/10.5489/cuaj.2526
Fig. 1. Management of castration-resistant prostate cancer (CRPC). PSADT: prostate-specific antigen doubling time. mCRPC: metastatic CRPC. 'Pending Health Canada approval in the chemo-naive setting. CRPC without mCRPC with minimal metastases or no symptoms Scondary hormonal Abiraterone theraphy Enzalutamide * Screen for metastases based on PSADT Docetaxel mCRPC with Post docetaxel symptoms Docetaxel Abiraterone Readium-223 Enzalutamide Cabazitaxel Radium-223 1. The optimal sequence of available options remains unknown. 2. Patients who have had little or no response to hormonal agents or who progress with minimal change in PSA or with significant visceral metastases should be considered for early chemotherapeutic options. 3. Radium-223 is not approved for patients with visceral metastases. 4. Whenever possible, clinical trials should remain the first choice in patients with CRPC.
|Printer friendly Cite/link Email Feedback|
|Publication:||Canadian Urological Association Journal (CUAJ)|
|Article Type:||Correction notice|
|Date:||Nov 1, 2015|
|Previous Article:||CUA Guideline: Management of ureteral calculi.|
|Next Article:||Correction in author list.|